Research and Markets: Global Biologics Perspectives - Complete Overview of the Biologic Market Dynamics

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/ad0ed0/ims_global_biologi) has announced the addition of the "IMS Global Biologics Perspectives" report to their offering.

This 128-page report provides a complete overview of the biologic market dynamics, focussing on market sizing elements:

  • worldwide, regional, country sales trends of biologics including pharmerging markets
  • major therapies and associated products sales trends
  • market positions and trends of the major players with insightful context outlining market characteristics and examining future perspectives that will drive and constraint this niche area

Key Topics Covered:

1. Introduction to Biologics

2. Characteristics Of the Biologic Market

3. the Biologic Market Dynamics

4. Competitive Landscape

5. Trends in Major therapy Areas

6. Lifecycle Management & Recent Product Launches

7. Biologic Pipeline & Predicted Blockbusters

8. Biosimilars & their Future Impact

9. Future Outlook for the Biologic Market

For more information visit http://www.researchandmarkets.com/research/ad0ed0/ims_global_biologi

Source: IMS Health



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.